MET233 + MET097

A **combination therapy** consisting of MET233 (an ultra-long acting amylin analog) and MET097 (an ultra-long acting GLP-1 receptor agonist), both administered as subcutaneous injections. This pairing is being developed by Metsera for the treatment of **obesity and overweight**, including individuals with or without type 2 diabetes. MET233 is designed to enhance weight loss and metabolic benefits, particularly when used in combination with MET097. - **MET233** mimics amylin, a hormone involved in regulating appetite and blood glucose, with engineering that allows for much longer activity and the potential for once-monthly dosing. - **MET097** is a fully-biased, ultra-long acting GLP-1 receptor agonist also designed for long duration and potential once-monthly dosing, supporting significant weight loss observed in clinical trials. Both agents utilize Metsera's HALO™ peptide lipidation platform, which extends their half-lives and facilitates co-formulation. The combination aims to deliver additive or synergistic effects on weight loss and metabolic control, addressing limitations of existing obesity drugs such as injection frequency, scalability, tolerability, and efficacy[3][4][7][9][8].

Brand names

MET-233/097

Other names

MET-233/097